# US 2023/0382910 A1 · Heteroaryl compounds for the treatment of pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0382910 A1
- Document ID: US20230382910A1
- Status: Published application
- Kind: A1
- Application number: 18/305,186
- Filed: 2023-04-21
- Published: 2023-11-30
- Earliest claimed: 2022-04-22
- Assignees: Vertex Pharmaceuticals Incorporated
- Applicants: Vertex Pharmaceuticals Incorporated
- Inventors: Mark Thomas Miller; Dennis James Hurley; Timothy Donald Neubert; Elamprakash Nesan Savariar; Urvi Patel; Sara Sabina Hadida Ruah; Jason McCartney; Jinglan Zhou; Robert Martin Demoret; Roman Askatovich Valiulin; Alexander Frederik Kintzer; Peter Webb; David Robert Slochower; Kathleen Aertgeerts; Elizabeth Mary Beck; Ronald Marcellus Alphonsus Knegtel; Ewa Iwona Chudyk; Joanne Louise Pinder
- Web page: https://patentgrep.com/patent/US20230382910A1

## CPC

- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 471/04: Ortho-condensed systems
- A61P 9/06: Antiarrhythmics
- A61P 25/02: for peripheral neuropathies
- C07D 215/22: attached in position 2 or 4
- C07D 215/233: only one oxygen atom which is attached in position 4
- C07D 215/48: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 215/60: N-oxides
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

## Claims

### Claim at position 1

1-122. (canceled)

### Claim 123

A compound of formula (I-E):
or a pharmaceutically acceptable salt thereof, wherein:
X5a is N or N+—O−;
R6a is H, halo, —CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)NH2, —NHC(O)NH(C1-C6 alkyl), —OH, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-(C1-C6 alkoxy), —(C1-C6 alkylene)-NH2, —(C1-C6 alkylene)-NH(C1-C6 alkyl), —(C1-C6 alkylene)-N(C1-C6 alkyl)2, —O(C1-C6 alkylene)-(C1-C6 alkoxy), —O(C1-C6 alkylene)-NH2, —O(C1-C6 alkylene)-NH(C1-C6 alkyl), —O(C1-C6 alkylene)-N(C1-C6 alkyl)2, —C(O)(C1-C6 alkyl), —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —C(O)OH, —C(O)O(C1-C6 alkyl), —C(NH)NH2, —C(S)NH2, —SO2NH2, or 5-10 membered heteroaryl comprising 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is optionally substituted with 1-2 Ra′;
R9a is H, halo, —CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —OH, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-(C1-C6 alkoxy), —(C1-C6 alkylene)-NH2, —(C1-C6 alkylene)-NH(C1-C6 alkyl), —(C1-C6 alkylene)-N(C1-C6 alkyl)2, —O(C1-C6 alkylene)-(C1-C6 alkoxy), —O(C1-C6 alkylene)-NH2, —O(C1-C6 alkylene)-NH(C1-C6 alkyl), —O(C1-C6 alkylene)-N(C1-C6 alkyl)2, —C(O)(C1-C6 alkyl), —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —C(O)OH, —C(O)O(C1-C6 alkyl), or —C(S)NH2;
each Ra′ is independently halo, —OH, C1-C6 alkyl, C1-C6 haloalkyl, —C(O)O(C1-C6 alkyl), or —C(O)NH2;
X3b is N or CR3b;
X6b is N or CR6b;
R2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —OH, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-C(O)OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —C(O)O(C1-C6 alkyl), —Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo;
R3b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —OH, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-C(O)OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo;
R4b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —OH, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —(C1-C6 alkylene)-OH, —(C1-C6 haloalkylene)-OH, —(C1-C6 haloalkylene)-C(O)OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —C(O)(O)(C1-C6 alkyl), —Si(C1-C6 alkyl)3, C6-C10 aryl, C3-C10 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or 4-10 membered heterocyclyl comprising 1-3 heteroatoms selected from nitrogen and oxygen, wherein cycloalkyl in said C3-C10 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo and said heterocyclyl is optionally substituted with 1-2 Rb′;
R5b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —OH, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-C(O)OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo;
R6b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —OH, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-C(O)OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo; and
each Rb′ is independently C1-C6 alkyl or C1-C6 haloalkyl,
provided that if X3b is CR3b and X6b is CR6b, then no more than three of R2b, R3b, R4b, R5b, and R6b are H.

### Claim 124 (depends on 123)

The compound of claim 123, or a pharmaceutically acceptable salt thereof, wherein:
R6a is H, halo, —CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —OH, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-(C1-C6 alkoxy), —(C1-C6 alkylene)-NH2, —(C1-C6 alkylene)-NH(C1-C6 alkyl), —(C1-C6 alkylene)-N(C1-C6 alkyl)2, —O(C1-C6 alkylene)-(C1-C6 alkoxy), —O(C1-C6 alkylene)-NH2, —O(C1-C6 alkylene)-NH(C1-C6 alkyl), —O(C1-C6 alkylene)-N(C1-C6 alkyl)2, —C(O)(C1-C6 alkyl), —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —C(O)OH, —C(O)O(C1-C6 alkyl), or —C(S)NH2;
R2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —OH, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-C(O)OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo; and
R4b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —OH, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —(C1-C6 alkylene)-OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo.

### Claim 125 (depends on 123)

The compound of claim 123, wherein the compound is of formula (I-F):
or a pharmaceutically acceptable salt thereof, wherein:
X3b is N or CH;
R2b is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —OH, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-C(O)OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —C(O)O(C1-C6 alkyl), —Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo;
R4b is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —OH, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —(C1-C6 alkylene)-OH, —(C1-C6 haloalkylene)-OH, —(C1-C6 haloalkylene)-C(O)OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —C(O)(O)(C1-C6 alkyl), —Si(C1-C6 alkyl)3, C6-C10 aryl, C3-C10 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or 4-10 membered heterocyclyl comprising 1-3 heteroatoms selected from nitrogen and oxygen, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo and said heterocyclyl is optionally substituted with 1-2 Rb′;
R5b is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —OH, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-C(O)OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo; and
each Rb′ is independently C1-C6 alkyl or C1-C6 haloalkyl.

### Claim 126 (depends on 123)

The compound of claim 123, wherein the compound is of formula (I-G):
or a pharmaceutically acceptable salt thereof, wherein:
X3b is N or CH;
R2b is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —OH, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-C(O)OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —C(O)O(C1-C6 alkyl), —Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo;
R4b is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —OH, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —(C1-C6 alkylene)-OH, —(C1-C6 haloalkylene)-OH, —(C1-C6 haloalkylene)-C(O)OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —C(O)(O)(C1-C6 alkyl), —Si(C1-C6 alkyl)3, C6-C10 aryl, C3-C10 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or 4-10 membered heterocyclyl comprising 1-3 heteroatoms selected from nitrogen and oxygen, wherein cycloalkyl in said C3-C10 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo and said heterocyclyl is optionally substituted with 1-2 Rb′; and
each Rb′ is independently C1-C6 alkyl or C1-C6 haloalkyl.

### Claim 127 (depends on 123)

The compound of claim 123, or a pharmaceutically acceptable salt thereof, wherein X5a is N.

### Claim 128 (depends on 123)

The compound of claim 123, or a pharmaceutically acceptable salt thereof, wherein X5a is N+—O−.

### Claim 129 (depends on 123)

The compound of claim 123, or a pharmaceutically acceptable salt thereof, wherein R9a is H, halo, C1-C6 alkyl, C1-C6 alkoxy, —C(O)OH, or —C(O)O(C1-C6 alkyl);
optionally wherein R9a is H, Cl, Br, —CH3, —OCH3, —OCH2CH3, —C(O)OH, or —C(O)OCH3.

### Claim 130 (depends on 123)

The compound of claim 123, or a pharmaceutically acceptable salt thereof, wherein R6a is H, —CN, C1-C6 alkoxy, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)NH2, —NHC(O)NH(C1-C6 alkyl), —OH, —O(C1-C6 alkylene)-(C1-C6 alkoxy), —O(C1-C6 alkylene)-N(C1-C6 alkyl)2, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —C(O)OH, —C(O)O(C1-C6 alkyl), —C(NH)NH2, —C(S)NH2, —SO2NH2, or 5-10 membered heteroaryl comprising 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is optionally substituted with 1-2 Ra′; and
each Ra′ is independently Cl, —OH, —CH3, —CH2CH3, —CF3, —C(O)OCH2CH3, or —C(O)NH2;
optionally wherein:
R6a is H, —CN, —OCH3, —OCH2CH2CH(CH3)2, —NH(CH3), —N(CH3)2, —NHC(O)NH2, —NHC(O)NHCH3, —OH, —OCH2CH2OCH3, —OCH2CH2N(CH3)2, —C(O)NH2, —C(O)NH(CH3), —C(O)N(CH3)2, —C(O)OH, —C(O)OCH3, —C(NH)NH2, —C(S)NH2, —SO2NH2,

### Claim 131 (depends on 123)

The compound of claim 123, or a pharmaceutically acceptable salt thereof, wherein X3b is N.

### Claim 132 (depends on 123)

The compound of claim 123, or a pharmaceutically acceptable salt thereof, wherein X3b is CR3b and R3b is H, halo, C1-C6 alkyl, or C1-C6 haloalkyl;
optionally wherein R3b is H, F, —CH3 or —CF3.

### Claim 133 (depends on 123)

The compound of claim 123, or a pharmaceutically acceptable salt thereof, wherein X6b is N.

### Claim 134 (depends on 123)

The compound of claim 123, or a pharmaceutically acceptable salt thereof, wherein X6b is CR6b and R6b is H, halo, or C1-C6 alkyl;
optionally wherein R6b is H, F, or —CH3.

### Claim 135 (depends on 123)

The compound of claim 123, or a pharmaceutically acceptable salt thereof, wherein R2b is H, halo, C1-C6 alkyl, C1-C6 alkoxy, —(C1-C6 alkylene)-OH, or —C(O)O(C1-C6 alkyl);
optionally wherein R2b is H, F, Cl, —CH3, —CH2CH3, —OCH3, —CH2OH, —CH2CH2CH2OH, or —C(O)OCH3.

### Claim 136 (depends on 123)

The compound of claim 123, or a pharmaceutically acceptable salt thereof, wherein R4b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 haloalkoxy, —(C1-C6 alkylene)-OH, —(C1-C6 haloalkylene)-OH, —(C1-C6 haloalkylene)-C(O)OH, —C(O)O(C1-C6 alkyl), —Si(C1-C6 alkyl)3, C6-C10 aryl, C3-C10 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or 4-10 membered heterocyclyl comprising 1-3 heteroatoms selected from nitrogen and oxygen, wherein cycloalkyl in said C3-C10 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo and said heterocyclyl is optionally substituted with 1-2 Rb′; and
each Rb′ is independently —CH3 or —CF3;
optionally wherein:
R4b is H, Cl, —CH3, —CH(CH3)2, —C(CH3)3, —C(CH3)2(CH2CH3), —CF3, —C(CH3)2(CHF2), —C(CH3)2(CF3), —CH2C(CH3)2F, —C(═CH2)(CF3), —CH═C(CH3)2, —OCF3, —C(CH3)2(CH2OH), —C(CH3)(CF3)(CH2OH), —C(CH3)(CF3)(C(O)OH), —C(O)OCH3, —Si(CH3)3, phenyl, 1-methylcyclopropyl, 1-trifluoromethylcyclopropyl, cyclobutyl, 1-methylcyclobutyl, 3,3-difluoro-1-methylcyclobutyl, cyclopentyl, 1-methylcyclopentyl, 1-trifluoromethylcyclopentyl, 3,3-difluoro-1-methylcyclopentyl, 4,4-difluoro-1-methylcyclohexyl,

### Claim 137 (depends on 123)

The compound of claim 123, or a pharmaceutically acceptable salt thereof, wherein R5b is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C3-C6 cycloalkyl;
optionally wherein R5b is H, F, Cl, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CF3, —OCH3, or cyclopropyl.

### Claim 138 (depends on 123)

The compound of claim 123, wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 139 (depends on 123)

The compound of claim 123, wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 140 (depends on 123)

A pharmaceutical composition comprising the compound of claim 123, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or vehicles.

### Claim 141 (depends on 123)

A method of inhibiting a voltage-gated sodium channel in a subject comprising administering to the subject the compound of claim 123, or a pharmaceutically acceptable salt thereof.

### Claim 142 (depends on 123)

A method of treating or lessening the severity in a subject of pain comprising administering to the subject an effective amount of the compound of claim 123, or a pharmaceutically acceptable salt thereof.

### Claim 143 (depends on 123)

A method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia comprising administering to the subject an effective amount of the compound of claim 123, or a pharmaceutically acceptable salt thereof.

### Claim 144 (depends on 123)

The compound of claim 123, wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 145 (depends on 144)

A pharmaceutical composition comprising the compound of claim 144, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or vehicles.

### Claim 146 (depends on 144)

A method of inhibiting a voltage-gated sodium channel in a subject comprising administering to the subject the compound of claim 144, or a pharmaceutically acceptable salt thereof.

### Claim 147 (depends on 144)

A method of treating or lessening the severity in a subject of pain comprising administering to the subject an effective amount of the compound of claim 144, or a pharmaceutically acceptable salt thereof.

### Claim 148 (depends on 144)

A method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia comprising administering to the subject an effective amount of the compound of claim 144, or a pharmaceutically acceptable salt thereof.

### Claim 149 (depends on 123)

The compound of claim 123, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 150 (depends on 123)

The compound of claim 123, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 151 (depends on 123)

The compound of claim 123, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 152 (depends on 123)

The compound of claim 123, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 153 (depends on 123)

The compound of claim 123, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 154

A compound of formula (I-D):
or a pharmaceutically acceptable salt thereof, wherein:
R6a is H, halo, —CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)NH2, —NHC(O)NH(C1-C6 alkyl), —OH, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-(C1-C6 alkoxy), —(C1-C6 alkylene)-NH2, —(C1-C6 alkylene)-NH(C1-C6 alkyl), —(C1-C6 alkylene)-N(C1-C6 alkyl)2, —O(C1-C6 alkylene)-(C1-C6 alkoxy), —O(C1-C6 alkylene)-NH2, —O(C1-C6 alkylene)-NH(C1-C6 alkyl), —O(C1-C6 alkylene)-N(C1-C6 alkyl)2, —C(O)(C1-C6 alkyl), —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —C(O)OH, —C(O)O(C1-C6 alkyl), —C(NH)NH2, —C(S)NH2, —SO2NH2, or 5-10 membered heteroaryl comprising 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is optionally substituted with 1-2 Ra′;
R9a is H, halo, —CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —OH, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-(C1-C6 alkoxy), —(C1-C6 alkylene)-NH2, —(C1-C6 alkylene)-NH(C1-C6 alkyl), —(C1-C6 alkylene)-N(C1-C6 alkyl)2, —O(C1-C6 alkylene)-(C1-C6 alkoxy), —O(C1-C6 alkylene)-NH2, —O(C1-C6 alkylene)-NH(C1-C6 alkyl), —O(C1-C6 alkylene)-N(C1-C6 alkyl)2, —C(O)(C1-C6 alkyl), —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —C(O)OH, —C(O)O(C1-C6 alkyl), or —C(S)NH2;
each Ra′ is independently halo, —OH, C1-C6 alkyl, C1-C6 haloalkyl, —C(O)O(C1-C6 alkyl), or —C(O)NH2;
X2b is N or CR2b;
X5b is N or CR5b;
X6b is N or CR6b;
Z is a 5-7 membered aromatic or nonaromatic ring optionally containing 1-3 heteroatoms selected from nitrogen and oxygen and is optionally substituted with one or more Rz;
R2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —OH, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-C(O)OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —C(O)O(C1-C6 alkyl), —Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo;
R5b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —OH, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-C(O)OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo;
R6b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)(C2-C6 alkyl), —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-C(O)OH, —C(O)(C1-C6 alkyl), —C(O)(C1-C6 haloalkyl), —Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo; and
Rz is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkenyl, —CN, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, or —C(O)OH.

### Claim 155

A compound of formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
R3c is H, halo, or C1-C6 alkyl;
R4c is H, halo, —CN, or C1-C6 alkoxy;
R5c is H, halo, —CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or —C(O)O(C1-C6 alkyl);
R6c is H, halo, —OH, —CN, C1-C6 alkoxy, C(O)NH2, or 5-10 membered heteroaryl comprising 1-3 heteroatoms selected from nitrogen and oxygen;
R9c is H, C1-C6 alkyl, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-O(C1-C6 alkyl), or —C(O)O(C1-C6 alkyl);
Y is
X3d is N or CR3d;
R2d, R3d, and R4d are defined as follows:
(i) R2d is H, halo, —OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or —(C1-C6 alkylene)-OH;
R3d is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy; and
R4d is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-(C1-C6 alkoxy), —Si(C1-C6 alkyl)3, —C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or —CN; or
(ii) R2d and R3d, together with the carbon atoms to which they are attached, form a ring of formula:
and
R4d is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —(C1-C6 alkylene)-OH, —(C1-C6 alkylene)-(C1-C6 alkoxy), —Si(C1-C6 alkyl)3, —C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or —CN; or
(iii) R2d is H, halo, —OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or —(C1-C6 alkylene)-OH; and
R3d and R4d, together with the carbon atoms to which they are attached, form a ring of formula:
R5d is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or —C(O)(C1-C6 alkyl);
R6d is H, halo, or C1-C6 alkyl;
R7d is C1-C6 alkyl; and
R9d is C1-C6 alkyl;
provided that:
(i) if Y′ is
and X3d is CR3d, then no more than four of R2d, R3d, R4d, R5d, and R6d are H; and
(ii) if Y′ is
and X3d is N, then no more than three of R2d, R4d, R5d, and R6d are H.

### Claim 156

A compound of formula (III):
or a pharmaceutically acceptable salt thereof, wherein:
X3k is N or CH;
X4k is N or CH;
X5k is N or CR5k;
X6k is N, N+—O−, or CR6k;
R5k is H, C1-C6 alkoxy, —OH, —OCH2CH2N(CH3)2, or —N(CH3)(CH2CH2OCH3);
R6k is H, —OH, C1-C6 alkoxy, or —C(O)NH2;
R2L is C1-C6 alkyl;
R4L is C1-C6 alkyl, C1-C6 haloalkyl, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-; and
R5L is H, halo, or C1-C6 alkyl,
provided that:
(i) at least one of X3k, X4k, and X5k is N, or X6k is N or N+—O−; and
(ii) no more than two of X3k, X4k, X5k, and X6k are N; and
(iii) if X6k is N+—O−, then X3k and X4k are CH, and X5k is CR5k; and
(iv) if X5k is N, then X4k is N.
